This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Allergic Rhinitis
and you are
between 18 and 60
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis

Provided treatments

  • Biological: Placebo
  • Biological: VAK694
  • Drug: Fluticasone
Tris trial is registered with FDA with number: NCT00929968. The sponsor of the trial is Novartis Pharmaceuticals and it is looking for 35 volunteers for the current phase.
Official trial title:
A Randomized, Double-blind, Placebo and Calibrator Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Doses of VAK694 in Subjects With Seasonal Rhinitis During Natural Exposure to Allergen